Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy

World J Gastroenterol. 2016 May 21;22(19):4685-94. doi: 10.3748/wjg.v22.i19.4685.

Abstract

Aim: To explore the role of mammalian target of rapamycin (mTOR) in the pathogenesis of cirrhotic cardiomyopathy and the potential of rapamycin to improve this pathologic condition.

Methods: Male albino Wistar rats weighing 100-120 g were treated with tetrachloride carbon (CCl4) for 8 wk to induce cirrhosis. Subsequently, animals were administered rapamycin (2 mg/kg per day). The QTc intervals were calculated in a 5-min electrocardiogram. Then, the left ventricular papillary muscles were isolated to examine inotropic responsiveness to β-adrenergic stimulation using a standard organ bath equipped by Powerlab system. Phosphorylated-mTOR localization in left ventricles was immunohistochemically assessed, and ventricular tumor necrosis factor (TNF)-α was measured. Western blot was used to measure levels of ventricular phosphorylated-mTOR protein.

Results: Cirrhosis was confirmed by hematoxylin and eosin staining of liver tissues, visual observation of lethargy, weight loss, jaundice, brown urine, ascites, liver stiffness, and a significant increase of spleen weight (P < 0.001). A significant prolongation in QTc intervals occurred in cirrhotic rats exposed to CCl4 (P < 0.001), while this prolongation was decreased with rapamycin treatment (P < 0.01). CCl4-induced cirrhosis caused a significant decrease of contractile responsiveness to isoproterenol stimulation and a significant increase in cardiac TNF-α. These findings were correlated with data from western blot and immunohistochemical studies on phosphorylated-mTOR expression in left ventricles. Phosphorylated-mTOR was significantly enhanced in cirrhotic rats, especially in the endothelium, compared to controls. Rapamycin treatment significantly increased contractile force and myocardial localization of phosphorylated-mTOR and decreased cardiac TNF-α concentration compared to cirrhotic rats with no treatment.

Conclusion: In this study, we demonstrated a potential role for cardiac mTOR in the pathophysiology of cirrhotic cardiomyopathy. Rapamycin normalized the inotropic effect and altered phosphorylated-mTOR expression and myocardial localization in cirrhotic rats.

Keywords: Cirrhotic cardiomyopathy; Inotropic effect; Mammalian target of rapamycin; Rapamycin; Rat.

MeSH terms

  • Action Potentials
  • Animals
  • Carbon Tetrachloride
  • Cardiomyopathies / enzymology
  • Cardiomyopathies / etiology*
  • Cardiomyopathies / pathology
  • Cardiomyopathies / physiopathology
  • Cardiotonic Agents / pharmacology
  • Chemical and Drug Induced Liver Injury / complications*
  • Chemical and Drug Induced Liver Injury / enzymology
  • Chemical and Drug Induced Liver Injury / pathology
  • Heart Rate
  • Isoproterenol / pharmacology
  • Liver Cirrhosis, Experimental / complications*
  • Liver Cirrhosis, Experimental / enzymology
  • Liver Cirrhosis, Experimental / pathology
  • Male
  • Myocardial Contraction
  • Myocardium / enzymology*
  • Myocardium / pathology
  • Papillary Muscles / drug effects
  • Papillary Muscles / enzymology*
  • Papillary Muscles / physiopathology
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Rats, Wistar
  • Signal Transduction
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism*
  • Tumor Necrosis Factor-alpha / metabolism
  • Ventricular Function, Left* / drug effects

Substances

  • Cardiotonic Agents
  • Protein Kinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • Carbon Tetrachloride
  • mTOR protein, rat
  • TOR Serine-Threonine Kinases
  • Isoproterenol
  • Sirolimus